Copyright
©2012 Baishideng.
World J Obstet Gynecol. Oct 10, 2012; 1(3): 35-39
Published online Oct 10, 2012. doi: 10.5317/wjog.v1.i3.35
Published online Oct 10, 2012. doi: 10.5317/wjog.v1.i3.35
Table 2 Worst grade 3 and 4 toxicities (National Cancer Institute-common toxicity criteria) per patient with platinum-resistant or platinum-refractory ovarian cancer undergoing weekly irinotecan + docetaxel and non-pegylated liposomal doxorubicin +/- gemcitabine + G-CSF n (%)
| Grade 3 and 4 toxicity | Weekly irinotecan + docetaxel | Liposomal doxorubicin +/- gemcitabine + G-CSF |
| Patients | 15 (100) | 12 (100) |
| Neutropenia grade 4 | 0 (0) | 2 (17) |
| Neutropenia grade 3 | 2 (13) | 4 (33) |
| Febrile neutropenia grade 4 | 1 (7) | 2 (17) |
| Leucopenia grade 3 | 2 (13) | 3 (25) |
| Leucopenia grade 4 | 0 (0) | 1 (8) |
| Thrombocytopenia grade 4 | 0 (0) | 2 (17) |
| Nausea grade 3 | 0 (0) | 1 (7) |
| Stomatitis/mucositis grade 3 | 0 (0) | 3 (25) |
| Diarrhea grade 3 | 4 (27) | 0 (0) |
| Diarrhea grade 4 | 1 (7) | 0 (0) |
| Infection grade 3 | 0 (0) | 2 (17) |
| Fatigue grade 3 | 1 (7) | 2 (17) |
| Pain grade 3 | 1 (7) | 2 (17) |
| Thromboembolism grade 3 | 2 (13) | 1 (7) |
| Weight gain grade 3 | 1 (7) | 0 (0) |
- Citation: Petru E, Volgger B, Bogner G, Angleitner-Boubenizek L, Deibl M, Schauer C, Reinthaller A, Wolfram G, Zeimet AG, Marth C. Platinum-resistant ovarian cancer: Prematurely stopped phase II Austrian AGO chemotherapy studies. World J Obstet Gynecol 2012; 1(3): 35-39
- URL: https://www.wjgnet.com/2218-6220/full/v1/i3/35.htm
- DOI: https://dx.doi.org/10.5317/wjog.v1.i3.35